Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCY 770

Next Previous
Drug Profile

SCY 770

Alternative Names: PXL-770; SCY-770

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poxel
  • Class Antihyperglycaemics; Cardiovascular therapies; Hepatoprotectants; Heterocyclic compounds; Naphthalenes; Potassium compounds; Pyridines; Small molecules; Urologics
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy; Autosomal dominant polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adrenoleucodystrophy; Non-alcoholic fatty liver disease
  • No development reported Autosomal dominant polycystic kidney disease; Cardiomyopathies
  • Discontinued Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for phase-I development in Autosomal-dominant-polycystic-kidney-disease(In volunteers) in Unknown (PO)
  • 31 Mar 2026 SCYNEXIS acquires PXL 770 from Poxel
  • 31 Mar 2026 SCYNEXIS plans phase II trial in Autosomal dominant polycystic kidney disease in quarter four of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top